Pharmaco-metabolomics: An emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets

Journal of Cellular Physiology

Volumn 227, Issue 7, 2012, Pages 2827-2831

  Corona, Giuseppe ^a   Rizzolio, Flavio ^a,b   Giordano, Antonio ^b   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CYCLOSPORIN; DOCETAXEL; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PARA CRESOL; PARACETAMOL; POLYUNSATURATED FATTY ACID; TACROLIMUS;

ANALYTIC METHOD; APOPTOSIS; ARTIFICIAL NEURAL NETWORK; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CHEMOSENSITIVITY; DNA METHYLATION; GAS CHROMATOGRAPHY; HIGH RESOLUTION MAGIC ANGLE SPINNING; HISTONE METHYLATION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL LEAST SQUARES REGRESSION; PH; PHARMACOMETABOLOMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOME; METABOLOMICS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84858631197     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24003     Document Type: Review

References (35)

1. Backshall A, Sharma R, Clarke SJ, Keun HC. 2011. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res 17: 3019-3028.
2. Baum CE, Price DK, Figg WD. 2010. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Ther 9: 341-342.
3. Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC, Nicholson JK. 2010. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 5: 1019-1032.
4. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. 2011. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12: 113-124.
5. Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G. 2011. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 11: 214-226.
6. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. 2009. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA. 106: 14728-14733.
7. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. 2006a. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
8. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. 2006b. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
9. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
10. Fiehn O. 2002. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 48: 155-171.
11. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F. 2011. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7: 523.
12. Glunde K, Serkova NJ. 2006. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7: 1109-1123.
13. Greving MP, Patti GJ, Siuzdak G. 2011. Nanostructure-initiator mass spectrometry metabolite analysis and imaging. Anal Chem 83: 2-7.
14. Grinde MT, Moestue SA, Borgan E, Risa O, Engebraaten O, Gribbestad IS. 2011. (13) C High-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR Biomed DOI:10.1002/nbm.1683.
15. Holmes E, Wilson ID, Nicholson JK. 2008. Metabolic phenotyping in health and disease. Cell 134: 714-717.
16. Klawitter J, Haschke M, Kahle C, Dingmann C, Klawitter J, Leibfritz D, Christians U. 2010. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 70: 241-251.
17. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK. 2005. The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 6: 691-699.
18. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG. 2011. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874.
19. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfor K, Kristensen GB, Gribbestad IS. 2007. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7: 11.
20. Ma Q, Lu AY. 2011. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63: 437-459.
21. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J. 2001. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 46: 49-57.
22. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, Koutcher JA. 2005. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11: 3503-3513.
23. Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, Fornier M, Morris PG, Biganzoli L, Luchinat C, Bertini I, Di Leo A. 2011. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol 22: 1295-1301.
24. Phapale PB, Kim SD, Lee HW, Lim M, Kale DD, Kim YL, Cho JH, Hwang D, Yoon YR. 2010. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin Pharmacol Ther 87: 426-436.
25. Phillips E, Mallal S. 2009. Successful translation of pharmacogenetics into the clinic: The abacavir example. Mol Diagn Ther 13: 1-9.
26. Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. 2004. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer 3: 174-181.
27. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR. 2001. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792.
28. Theodoridis G, Gika HG, Wilson ID. 2011. Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass Spectrom Rev 30: 884-906.
29. Wang X, Yan SK, Dai WX, Liu XR, Zhang WD, Wang JJ. 2010. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer. Int J Cancer 127: 2841-2850.
30. Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body. J Gen Physiol 8: 519-530.
31. Waterman DS, Bonner FW, Lindon JC. 2009. Spectroscopic and statistical methods in metabonomics. Bioanalysis 1: 1559-1578.
32. Wei R. 2011. Metabolomics and its practical value in pharmaceutical industry. Curr Drug Metab 12: 345-358.
33. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. 2010. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88: 45-51.
34. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
35. Zhang S, Nagana Gowda GA, Ye T, Raftery D, 2010. Advances in NMR-based biofluid analysis and metabolite profiling. Analyst 135: 1490-1498.